ArticleCardiovascular and interventional radiology2026
Transarterial Embolization for the Treatment of Symptomatic Hip Osteoarthritis.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Periarticular Embolization as an Alternative Treatment for Surgery-Ineligible Patients with Hip Osteoarthritis: A Prospective Comparative Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the safety and clinical effectiveness of transarterial embolization (TAE) using temporary embolic agents in patients with symptomatic hip osteoarthritis (OA) refractory to conservative treatment. MATERIALS AND
methodsThis single-centre retrospective analysis included patients undergoing TAE between January 2023 and April 2025. Eligibility required ≥ 3 months of clinically and radiographically confirmed hip OA unresponsive to conservative therapy. Embolization was performed using rapidly resorbable gelatin microspheres or imipenem/cilastatin. Outcomes included technical success, adverse events, and patient-reported outcomes (numeric rating scale [NRS] pain; Hip Disability and Osteoarthritis Outcome Score [HOOS]) assessed at baseline and up to 12 months. Clinically meaningful improvement was defined using minimum clinically important difference (MCID) thresholds (≥ 2 points for NRS; ≥ 10 points for HOOS).
resultsForty-one patients (median age 65 years) underwent TAE with a technical success rate of 97.5% (40/41). The lateral circumflex femoral artery was embolized in all cases, with additional internal iliac branches treated in 27.5% (11/40). No major or moderate adverse events occurred; minor transient skin discoloration was observed in 7.3% (all after imipenem/cilastatin). Median NRS decreased from 7 to 4 at 12 months (p < .001), with significant improvement across all HOOS domains. MCID was achieved in 64.3% for NRS and 85-92% for HOOS. Two patients (4.9%) underwent total hip replacement.
conclusionTAE using temporary embolic agents was associated with sustained pain reduction and functional improvement at 12 months with a favourable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.